Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia | Universitas Indonesia Hospital, Universitas Indonesia, Depok, Indonesia.
Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Curr Neurovasc Res. 2021;18(3):360-363. doi: 10.2174/1567202618666210927095613.
Coronavirus disease-19 (COVID-19) is an infectious disease with high morbidity and mortality rates. Indonesia had reported a 2.8% of mortality rate up to June 2021.
A strategy to control the virus spreading is by vaccination. The Indonesian Food and Drug Monitoring Agency had approved the use of CoronaVac, an inactivated virus vaccine developed by Sinovac. Most Adverse Events Following Immunization (AEFI) for Corona- Vac are mild, and the most common symptoms are injection-site pain, headache, and fatigue. Neurovascular adverse events, including thrombosis or ischaemic stroke after receiving CoronaVac have not previously been reported.
Correspondingly, we reported three patients with an Acute Ischaemic Stroke (AIS) after the administration of CoronaVac in our hospital.
新型冠状病毒肺炎(COVID-19)是一种具有高发病率和死亡率的传染病。截至 2021 年 6 月,印度尼西亚报告的死亡率为 2.8%。
控制病毒传播的策略是接种疫苗。印度尼西亚食品和药物监测局已批准使用科兴公司开发的灭活病毒疫苗 CoronaVac。CoronaVac 最常见的不良反应(AEFI)为轻度,最常见的症状是注射部位疼痛、头痛和疲劳。接种 CoronaVac 后发生的神经血管不良事件,包括血栓形成或缺血性中风,以前尚未报道过。
相应地,我们报告了在我们医院中,有 3 名患者在接种 CoronaVac 后发生急性缺血性脑卒中(AIS)。